52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism — Stella
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
(20 sites) United States
Children's Hospital Los Angeles, Los Angeles, California Rady Children's Hospital - San Diego, San Diego, California University of California San Francisco, San Francisco, California Children's Hospital Colorado, Aurora, Colorado Nemours Children's Specialty Care - Jacksonville, Jacksonville, Florida Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois Boston Children's Hospital, Boston, Massachusetts University of Massachusetts Memorial Medical Center, Worcester, Massachusetts M Health Fairview U Minnesota, Minneapolis, Minnesota Washington University School of Medicine in St. Louis, St Louis, Missouri The DOCS, Las Vegas, Nevada Children's Hospital at Montefiore, The Bronx, New York OUHSC Pediatric Diabetes & Endocrinology, Oklahoma City, Oklahoma Children's Hospital of Philadelphia, Philadelphia, Pennsylvania Prisma Health Children's Hospital - Midlands, Columbia, South Carolina MedResearch, El Paso, Texas Texas Children's Hospital, Houston, Texas Primary Children's Hospital, Salt Lake City, Utah Seattle Children's Hospital, Seattle, Washington MultiCare Institute for Research & Innovation, Tacoma, Washington
Key details Sponsor
Halozyme Therapeutics
Enrollment target
~100 participants
Primary completion
March 2028
Age range
12 Years – 17 Years
Last updated February 2026